Dr. Reddy's Laboratories Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DRREDDY.BO | IPCALAB.BO | DIVISLAB.BO | AUROPHARMA.NS | ZYDUSLIFE.BO | GRANULES.NS | |
|---|---|---|---|---|---|---|
| Market cap | 1.13T | 494.67B | 2.69T | 1.03T | 1.19T | 216.71B |
| P/E (TTM) | 20.1 | 37.8 | 92.1 | 25.9 | 28.6 | 27.8 |
| Forward P/E | 24.8 | 27.7 | 67.0 | 19.0 | 24.0 | 20.7 |
| Price/book | 3.0 | 6.1 | 16.1 | 2.6 | 4.3 | 3.0 |
| Dividend yield | 0.65% | 0.30% | 0.30% | — | 0.08% | 0.22% |
| 1-year change | +0.33% | +51.51% | +45.74% | +49.48% | +27.10% | +43.88% |
| Today | −0.82% | −1.18% | +1.14% | +4.69% | +0.54% | −0.02% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All DRREDDY.BO news ›Dr. Reddy's Laboratories allocates 5,91,270 equity shares under its employee stock option plan
Dr. Reddy's Laboratories has allotted 5,91,270 equity shares to employees under its stock option scheme, enriching its issued share capital to Rs. 83,52,72,555. Dr. Reddy's Laboratories allocates 5,91,270 equity shares under its employee…
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
A biosimilar approval target and supply-chain fixes set up margin expansion as core growth offsets legacy drug headwinds. On the earnings call for its 2027 fiscal second quarter, ended Sept. 30, held on Oct. 23, 2026, Dr. Reddy's (RDY…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).... NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims…
Dr Reddy's Laboratories Q2 net profit falls 36 pc to Rs 913 cr
New Delhi, Oct 23 (PTI) Dr Reddy’s Laboratories on Friday reported a 36 per cent decline in consolidated net profit to Rs 913.4 crore for the September quarter, impacted by lower lenalidomide sales and a fall in API volume offtake. The…
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call October 23, 2026 10:00 AM EDT Aishwarya Sitharam - Lead of Investor RelationsMannam Venkatanarasimham - CFO & Member of the Management CouncilErez Israeli - CEO & Member of the…
DR Reddy Laboratories Email Format
Centralisez vos sources de données first-party et third-party dans Clay Achetez des données auprès de plus de 200 fournisseurs au même endroit Suivez les changements de poste, les promotions et d’autres signaux Combinez plusieurs…
Dr Reddy's Laboratories stock in focus as USFDA completes pre-approval inspection at FTO-9 plant
Dr. Reddy's Laboratories Ltd shares will be in focus on Thursday morning after the company disclosed that the United States Food and Drug Administration (USFDA) completed a pre-approval inspection at its FTO-9 manufacturing facility in…
Dr Reddys Laboratories receives two observations for Andhra Pradesh facility
New Delhi, Oct 8 (PTI) Drug major Dr Reddy’s Laboratories has received a Form 483 with two observations from the US Food and Drug Administration (USFDA) following an inspection at its manufacturing facility in Pydibhimavaram, Andhra…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- news18.com3
- prnewswire.com2
- seekingalpha.com2
- businesstoday.in1
- businessupturn.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.